Leading the pack or following the herd? The consequences of pipeline asset clustering around targets and implications for portfolio decisions
AcademicLabs
58:50
How much does timing matter in drug development? Does being first, second, or fifth into a therapeutic space really change your company’s fortunes? And what can past examples tell us about smarter portfolio decisions today?
Join pharma strategist Mark Tillotson as he unpacks:
- The relationship between order of entry into R&D programs and long-term company value.
- Case studies where herding paid off - and where it destroyed value.
- Practical implications for how pharma and biotech should approach pipeline and portfolio choices.
Mark will share a fresh analysis powered by recent data - made feasible by AcademicLabs.com - to explore how companies can avoid the risks of herd behavior and redirect resources to higher-impact opportunities.
At the end, you’ll also get a quick look at how you can try the platform and the AI yourself with a complimentary two-week trial.
Speakers
Mark Tillotson
Pharma Strategist
Mark Tillotson is a global pharma strategist with deep experience guiding portfolio, pipeline, positioning and commercialization decisions. He has worked across a wide variety of areas, including rare diseases, cardiometabolic, neuroscience, specialty care and oncology. With 15 years of Life Science commercial experience allowing him to connect downstream results to upstream decisions, Mark uses structured approaches blending qualitative and quantitative data to advise organizations on how to build differentiated, innovation-driven portfolios and prepare them for commercial success.
Arne Smolders
CEO @ AcademicLabs
Arne Smolders is a scientist turned entrepreneur and the founder & CEO of AcademicLabs. With a background in aging biology research at Ghent University (2011-2015), where he explored the molecular pathways that influence longevity, Arne experienced first-hand how difficult it can be to connect bright scientific ideas with the right expertise, technologies and resources. Motivated by this challenge, he left his PhD program to focus fully on building AcademicLabs with the mission of breaking down silos and bringing transparency to global R&D to facilitate collaboration and impactful research and innovation. Today, AcademicLabs.com is a global AI-driven early-stage research & innovation scouting platform relied upon by scientific analysts, business development teams and researchers at leaders in the biopharma ecosystem. With the entire early-stage research world at your fingertips, you easily find in one place ideal KOLs, rising stars, research collaborators, biotech startups, pharma research, biotech investors, CROs, or identify novel technologies, assets, targets and much more across new ongoing and funded research projects, publications, patents, clinical trials, news, company websites and more.
Replays
See allLeading the pack or following the herd? The consequences of pipeline asset clustering around targets and implications for portfolio decisions
58:50